How the biological processes cause progression in different types of MS.
A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.
Screening of almost 250 medications has identified clomipramine as a possible treatment for progressive MS.
The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US
Video from Caroline Sincock who recently joined the International Progressive MS Alliance
Researchers and health professionals gather for the latest updates and research findings on treatment, care and management of MS
Challenges and next steps considered
A recent study has failed to show any benefit for Rituximab in people with secondary progressive MS